117
A vaccination against skin cancer from the US company Moderna shows promising results in a clinical study with a small group of patients. The risk of a new illness was reduced by 40 percent. 157 patients with a high risk of cancer recurrence were included in the scientific study. Of them, 50 received the previous standard therapy with the so-called checkpoint inhibitor pembrolizumab. Such immunotherapy is intended to be the body’s own